Can a simple infusion shield kidneys during heart surgery?

NCT ID NCT06168799

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a drug called ilofotase alfa can prevent kidney damage in people undergoing open heart surgery. 271 patients received either the drug or a placebo before and after surgery. The goal was to see if the drug could keep kidney function stable and reduce serious kidney events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ilofotase alfa

What this could lead to

If it works, this could provide a way to protect kidneys during heart surgery, reducing the risk of long-term kidney problems.

What could go wrong

This is a Phase 2 trial with only 271 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPEN-HEART SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research site

    Munich, Germany